Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease

NCT05463731 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05463731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05463731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
August 1, 2022
Completion date
May 12, 2026
Enrollment
1,667 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease